

Session Title: #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Session Type: Special Session

Date: Saturday, June 5

Location: N Hall B1

Time: 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Daniel D. Von Hoff, MD

Session Title: #81: New Treatments for Sarcoma in Children, Adolescents, and Young Adults

Session Type: Education Session

Date: Saturday, June 5

Location: S504

Time: 1:15 PM - 2:30 PM

- Optimal approaches for achieving local control in children, adolescents, and young adults with sarcoma

R. Lor Randall, MD, FACS

- Optimal strategies for controlling metastatic disease in children, adolescents, and young adults with sarcoma

Douglas S. Hawkins, MD

- Treatment of childhood, adolescent, and young adult sarcoma. Where do we go from here?

Stephen X. Skapek, MD

Session Title: #167: Highlights of the Day I including Clinical Trials Participation Awards

Session Type: Highlights of the Day

Date: Sunday, June 6

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day I including Clinical Trials Participation Awards
Everett E. Vokes, MD
- Clinical Trials Participation Awards
Douglas W. Blayney, MD
- Discussion: Lymphoma and Plasma Cell Disorders
Bruce D. Cheson, MD
- Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy
Alan B Sandler, MD
- Discussion: Patient and Survivor Care
Gretchen Genevieve Kimmick, MD
- Discussion: Melanoma/Skin Cancers
F. Stephen Hodi, MD

Session Title: #31: Controversies in the Management of Desmoid Tumors

Session Type: Education Session

Date: Sunday, June 6

Location: S406 (Vista Room)

Time: 8:00 AM - 9:15 AM

- Local management of desmoid tumors
Murray F. Brennan, MD
- Non-operative management of desmoids with or without systemic therapy
Sylvie Bonvalot, MD, PhD
- Molecular Markers of Desmoid recurrence
Alexander Lazar, MD, PhD

Session Title: #34: Creative Approaches to Advanced and Metastatic Sarcoma

Session Type: Education Session

- Management of sarcoma patient with lung metastasis - minimally invasive/non resection approaches
Raja Michael Flores, MD
 - Role of radiation for treatment of advanced/metastatic sarcoma
Brian O'Sullivan, MD
 - Novel systemic approaches for the management of advanced/metastatic sarcoma
William D. Tap, MD
-

Session Title: #65: Lessons Learned from Clinical Trials in Gastrointestinal Stromal Tumor

Session Type: Education Session

Date: Sunday, June 6

Location: S406 (Vista Room)

Time: 11:30 AM - 12:45 PM

- The role of Adjuvant imatinib after resection of localized primary GIST: An update on the Z9001 trial, optimal duration of therapy
Ronald P. DeMatteo, MD
 - Combination therapy with established and novel targeted agents to improve outcomes in patients with advanced GIST
Jean-Yves Blay, MD, PhD
 - Dosing the unusual patient with non exon 9/11 GIST
Michael C. Heinrich, MD
-

Session Title: #143: Plenary Session including Science of Oncology Award and Lecture

Session Type: Plenary Session

Date: Sunday, June 6

Location: N Hall B1

Time: 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture
Douglas W. Blayney, MD
- Plenary Session including Science of Oncology Award and Lecture
Daniel F. Hayes, MD
- Plenary Session including Science of Oncology Award and Lecture
Frank McCormick, PhD, FRS

- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

Robert A Burger

- Discussion

Elizabeth A. Eisenhauer, MD

- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).

Elisabeth A. Quoix

- #3-Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC).

Yung-Jue Bang

- Discussion

Martin J. Edelman, MD

- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

Steven O'Day, MD

- Discussion: Ipilimumab: The light at the end of the tunnel?

Vernon K Sondak, MD

Session Title: #212: Sarcoma

Session Type: General Poster Session

Date: Sunday, June 6

Location: S Hall A2

Time: 2:00 PM - 6:00 PM

48A #10034-Prognostic value of the most frequent mutations in GIST: Results of the French population-based prospective study MolecGIST.

Jean-François Emile

48B #10035-Combination of targeted therapy (imatinib) with immunotherapy (peginterferon α-2b) to overcome drug resistance and tumor stem cells in gastrointestinal stromal tumors (GIST).

Lei L. Chen

48C #10036-Phase I/II study of TH-302 combined with doxorubicin in soft tissue sarcoma.

Lee D. Cranmer

48D #10037-Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study.

Hans Gelderblom

48E #10038^ -Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST.

Stephan Richter

48F #10039-Identification of oncogenic events in gastrointestinal stromal tumors (GISTs) by combined gene expression and copy number analysis.

Margherita Nannini

48G #10040-Soluble factors (SF) associated with efficacy and toxicity of pazopanib (PZB) in advanced soft tissue sarcoma (STS) patients (pts): An EORTC-STBSG study.

Stefan Sleijfer

48H #10041-Radiofrequency ablation of lung metastases arising from sarcoma.

Jean Palussiere

49A #10042-Improvement in the survival for adult soft tissue sarcoma with adjuvant anthracycline chemotherapy combination: A meta-analysis and metaregression.

Sergio L Afonso, MD

49B #10043-BRAF V600E mutations in benign and malignant peripheral nerve sheath tumors.

Cesar Serrano

49C #10044-Use of a genome-wide single nucleotide polymorphism array-based chromosomal analysis to evaluate uniparental disomy (UPD) in gastrointestinal stromal tumors (GIST).

Nelson Lourenço

49D #10045-Trends in survival for metastatic soft-tissue sarcoma: A French Sarcoma Group (GSF) database analysis.

Antoine Italiano

49E #10046-Novel reconstruction using tumor-containing autologous bone grafts frozen in liquid nitrogen.

Hiroyuki Tsuchiya

49F #10047-Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib (IM).

Buu-Phuc Nguyen

49G #10048[^]-Multicenter, single-arm, two-stage phase II trial of everolimus (RAD001) with imatinib in imatinib-resistant patients (pts) with advanced GIST.

Peter Hohenberger

49H #10049-Targeting CHK1 pathway to induce cytotoxic response to histone deacetylase inhibitors and evaluating the synergistic effects of CHK1 and HDAC inhibitors in human soft tissue sarcoma cell lines and primary tumor xenografts.

Damon R. Reed

50A #10050-CSPG4 and B7-H3 as prognostic biomarkers in chordoma.

Andrew Schoenfeld

50B #10051-Outcome of patients (pts) with PDGFRAD842V mutant gastrointestinal stromal tumor (GIST) treated with imatinib (IM) for advanced disease.

Pierre Biron

50C #10052-Coexistence of gastrointestinal stromal tumor (GIST) with desmoid tumor (DT): Case series of 22 patients.

Amaury Gerard Dumont

50D #10053-Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumor (GIST).

Oluwatojin Oladeji

50E #10054-Development of a nomogram to predict overall survival in patients with locally advanced or metastatic gastrointestinal stromal tumor receiving first-line treatment with imatinib.

David Goldstein

50F #10055-Gastrointestinal stromal tumor (GIST) of the rectum and pararectal space: A French Sarcoma Group (FSG) retrospective review.

Florence Duffaud

50G #10056-Surgery of residual disease of myxoid liposarcoma (MLS) patients responding to trabectedin.

Roberta Sanfilippo

50H #10057-Quality of randomized controlled trials reporting in the treatment of sarcomas.

Maud Toulmonde

51A #10058-Antiproliferative effect of mTOR inhibitor everolimus (EV) alone or in combination with multikinase inhibitor (MK-I) sorafenib (SOR) in preclinical models of osteosarcoma (OS).

Ymera Pignochino

51B #10059-Sunitinib (SU)-related hypertension in a randomized placebo (P)-controlled trial of GIST patients (pts).

Michael Ewer

51C #10060-A phase II trial of imatinib (IM) in relapsed, nonresectable chondrosarcoma (CS) expressing platelet-derived growth factor receptor- α ; or - β ; (PDGFR- α ; /PDGFR- β ;): An Italian Sarcoma Group study.

Giovanni Grignani

51D #10061-Adjuvant imatinib therapy of 208 gastrointestinal stromal tumor (GIST) patients: Dose, duration, and risk assessment.

Jonathan C. Trent

51E #10062-Quality of life (QoL) in osteosarcoma: First results of the presurgery treatment period of EURAMOS-1 (NCT00134030).

Andreas Wiener

51F #10063-High-dose photon-beam radiation therapy in chordoma: A single institution retrospective analysis.

Claudia Sangalli

51G #10064-Impact of imatinib plus best supportive care in imatinib and sunitinib exposed patients with refractory advanced gastrointestinal stromal tumor.

Akira Sawaki

51H #10065-Metronomic oral cyclophosphamide (CPM) and prednisolone in elderly patients (pts) with inoperable or metastatic soft tissue sarcoma (STS).

Olivier Mir

52A #10066-PAX3/7-FOXO1 fusions by fluorescent in situ hybridization (FISH) using an adult rhabdomyosarcoma tissue microarray.

Sarah N. Dumont

52B #10067-Cutaneous angiosarcoma of the head and neck.

Prakash K Pandalai

52C #10068-Quality of surgical margins and local recurrence in primary extremity soft tissue sarcoma (STS).

Sylvie Bonvalot, MD, PhD

52D #10069-Immunohistochemical study and fluorescent in situ hybridization analysis of JAZF1 in 67 cases of endometrial stromal tumors collected in a tissue microarray.

Juliette Duclos

52E #10070-Prognostic factors of KIT-negative GIST-like patients (KNGL): A Spanish Group for Sarcoma Research (GEIS) study.

Javier Martin Broto

52F #10071-Absence of correlation between the molecular subtype of COL1A1-PDGFB fusion gene and the clinico-histopathological features of dermatofibrosarcoma protuberans: Analysis of 35 novel cases and review of 137 cases from the literature.

Damien Giacchero

52G #10072-Nonstandard dosing in gastrointestinal stromal tumors: A registry observation.

Peter W. T. Pisters

52H #10073-Imaging-guided core needle biopsies (CNB) compared to surgical biopsies (SB) for soft tissue tumors: A cost-effectiveness analysis.

Sophie Taieb

53A #10074-First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histologic soft tissue sarcoma (STS) subtypes and as a prognostic factor for MPNST: An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) study.

Judith R. Kroep

53B #10075-First report of outcomes with neoadjuvant chemoradiotherapy (NCR) using weekly intravenous (IV) cisplatin with radiation (NCWR) for treatment of stage II and III extremity soft tissue sarcoma (STS).

Kelly Kevelin Curtis

53F #10076-Antitumor activity of pemetrexed (Pem) in second-line advanced/metastatic osteosarcomas: A multicenter phase II study.

Nguyen Bin Bui

53G #10077-Evaluation of quality of life in patients treated with resection and reconstruction of the upper or lower limb for bone sarcomas.

Pietro Ruggieri

53H #10078-Prognostic significance of proliferation markers and telomerase activity in gastrointestinal stromal tumors.

Alena Augustinakova

54A #10079-Effect of adjuvant radiotherapy on survival in localized limb or trunk wall well-differentiated liposarcoma (WDLPS).

Aude Duret

54B #10080-Efficacy of neoadjuvant doxorubicin and ifosfamide (AI) in myxoid /round cell liposarcoma (MRCL): The M.D. Anderson Cancer Center experience (MDACC).

Daniela Katz

54F #10081-Assessment of early response to imatinib 800 mg after 400 mg progression by 18 f-fluorodeoxyglucose positron emission tomography in patients with metastatic gastrointestinal stromal tumor.

Adriel Rodriguez Espíndola

54G #10082-Effect of radiation therapy on survival of patients with surgically resected retroperitoneal sarcoma: A population-based matched pair study.

Audrey Choi, BA

54H #10083-Sunitinib as the second-line therapy for advanced GISTs after failure of imatinib in Korean patients.

Min-Hee Ryu

55A #10084-Gastrointestinal stromal tumors (GISTs) and other cancers: Cambridge GIST Study Group experience.

Venkata Ramesh Bulusu, MBBS, MSc, MD

55B #10085-Impact of subspecialty, clinical volume, and years of practice in selection of treatment sequencing in the management of localized extremity soft tissue sarcoma.

Robert J. Canter

55C #10086-Pattern of growth of retroperitoneal sarcoma: Do they push or infiltrate adjacent organs? Analysis of a single institution series.

Chiara Erminia Mussi

55D #10087-Neoadjuvant, adjuvant, and palliative treatment with imatinib in patients with gastrointestinal stromal tumors.

Bengt E Nilsson

55E #10088-Long-term results of primary re-excision after unplanned resection of a soft tissue sarcoma of the extremities and trunk.

Matthias Peiper, Prof., Dr.

55F #10089-Effect of histone deacetylase inhibitor (HDACI) PCI-24781 on chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines.

Edwin Choy, MD, PhD

55G #10090-Evaluation of nilotinib (N) in advanced GIST previously treated with imatinib mesylate (IM) and sunitinib (S).

Carolina Cauchi

55H #10091-Measurement of interstitial fluid pressure (IFP) and circulating biomarkers in soft tissue sarcoma (STS): An exploratory phase II clinical and correlative study of sorafenib (SOR) in patients with refractory STS (NCI Protocol 6948).

Chandrajit P. Raut

56A #10092-The GOLD reGISTry: A global observational registry collecting longitudinal data on patients with advanced GIST-Second annual summary.

Matias Chacon

56B #10093-Extraskelatal osteosarcoma: Clinicopathologic features and results of multimodal management.

Nicola Fabbri, MD

56C #10094-Analysis of prognostic factors of pediatric-type sarcomas in adult patients.

Hee Kyung Ahn

56D #10095-Radiological tissue changes and pathological response in localized high-grade soft tissue sarcomas (STS) as predictors of outcome after neoadjuvant treatment with chemoradiotherapy (CRT).

Antonio Lopez-Pousa

56E #10096-Clear cell sarcoma (CCR): Clinical behavior and response to chemotherapy.

Silvia Stacchiotti

56F #10097-A national registry for the off-label use of targeted therapies in patients (pts) with malignant mesenchymal tumors: A retrospective study from the GSF-GETO.

Jacques-Olivier Bay

56G #10098-Systemic therapy in clear cell sarcoma.

Anastasia Constantinidou

Session Title: #168: Highlights of the Day II including Partners in Progress Award

Session Type: Highlights of the Day

Date: Monday, June 7

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award

Kim Allyson Margolin, MD

- Highlights of the Day II including Partners in Progress Award

Douglas W. Blayney, MD

- Partners in Progress Award Recipient

Ellen V. Sigal, PhD

- Discussion: Genitourinary (Prostate) Cancer

Nicholas J. Vogelzang, MD

- Discussion: Gastrointestinal (Colorectal) Cancer

Howard S. Hochster, MD

- Discussion: Gynecologic Cancer

Claire F. Verschraegen, MD

- Discussion: Myeloma
Jean L. Harousseau, MD
 - Discussion: Cancer Prevention/Epidemiology
Scott Michael Lippman, MD
-

Session Title: #106: Translocation-specific Sarcomas: Can Molecular Targets Translate to Therapeutics?

Session Type: Education Session

Date: Monday, June 7

Location: S406 (Vista Room)

Time: 8:00 AM - 9:15 AM

- Target genes of chimeric transcription factors in pediatric sarcomas: a source of potential therapeutic targets
Marc Ladanyi, MD
 - Targeting protein products of sarcoma specific translocations with small molecules
Jeffrey Toretsky, MD
 - IGF1R targeting of translocation-associated sarcomas
Lee J. Helman, MD
-

Session Title: #166: Sarcoma

Session Type: Oral Abstract Session

Date: Monday, June 7

Location: S406 (Vista Room)

Time: 1:00 PM - 4:00 PM

- Sarcoma
Richard Riedel, MD
- Sarcoma
Mark Agulnik, MD
- #10000-Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study.
Alberto S. Pappo, MD

- #10001-AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): Phase II results.

William D. Tap, MD

- #10002-Combination mTOR+IGF-IR inhibition: Phase I trial of everolimus and CP-751871 in patients (pts) with advanced sarcomas and other solid tumors.

Richard Hong Hui Quek

- Discussion

Jeffrey Toretsky, MD

- #10003-Localized, high-risk soft tissue sarcomas (STS) of the extremities and trunk wall in adults: Three versus five cycles of full-dose anthracyclin and ifosfamide adjuvant chemotherapy: A phase III randomized trial from the Italian Sarcoma Group (ISG) and Spanish Sarcoma Group (GEIS).

Alessandro Gronchi

- #10004-A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO).

Claire F. Verschraegen, MD

- #10005-Identification of selective inhibitors of dedifferentiated liposarcoma cells by high-throughput screening (HTS).

Christina Vadala Angeles, MD

- Discussion

Andrew J. Wagner, MD, PhD

- #10006-Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001.

Christopher Corless

- #10007-In vitro activity of novel KIT/PDGFRα switch pocket kinase inhibitors against mutations associated with drug-resistant GI stromal tumors.

Michael C. Heinrich, MD

- #10008-Succinate dehydrogenase in KIT/PDGFRα wild-type gastrointestinal stromal tumors.

Katherine A. Janeway

- Discussion

Robert D Marsh, MD

Session Title: #169: Highlights of the Day III

Session Type: Highlights of the Day

Date: Tuesday, June 8

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day III
Kathy Miller, MD
- Discussion: Breast Cancer - Local/Regional and Adjuvant Therapy
Kathy Miller, MD
- Discussion: Lung Cancer - Metastatic
Charles M. Rudin, MD, PhD
- Discussion: Sarcoma
Gary K. Schwartz, MD
- Discussion: Gastrointestinal (Noncolorectal) Cancer
C. D. Blanke, MD
- Discussion: Head and Neck Cancer
Everett E. Vokes, MD

Session Title: #191: Sarcoma

Session Type: Poster Discussion Session

Date: Tuesday, June 8

Location: S103

Time: 8:00 AM - 12:00 PM

- Sarcoma
Anette Duensing, MD
 - Sarcoma
Mark Agulnik, MD
- 1 #10009-Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma.
Scott Schuetze
- 2 #10010-Advanced phase I/II evaluation of tumor-targeted gene delivery: Intravenous retrovector encoding mutant anticyclin G1 as stand-alone therapy for chemotherapy-resistant bone and soft tissue sarcoma.

3 #10011-Imatinib in the treatment of tenosynovial giant-cell tumor and pigmented villonodular synovitis.

Vinod Ravi

4 #10012-Imatinib mesylate for the treatment of locally advanced and/or metastatic pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).

Philippe Alexandre Cassier

5 #10013-Activity of sorafenib against desmoid tumor/deep fibromatosis (DT/DF).

Mrinal M. Gounder, MD

6 #10014-Sunitinib malate (SM) in alveolar soft part sarcoma (ASPS).

Elena Palassini

- Discussion

Ian Robert Judson, MD

7 #10015-Phase II trial of nilotinib as third-line therapy for gastrointestinal stromal tumor (GIST) patients in Japan.

Toshirou Nishida, MD, PhD, FACS

8 #10016-Nilotinib for patients with advanced GIST who failed imatinib and sunitinib: Negative effect of prior major gastrectomy on exposure to nilotinib.

Kyu-pyo Kim

9 #10017[^]-Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3.

Peter Reichardt

10 #10018-Validation of Joensuu risk criteria for primary resectable gastrointestinal stromal tumors.

Piotr Rutkowski

11 #10019-Correlation of the topography of *KIT* exon 11 mutation with primary GIST location and predictive value for PFS in patients with advanced GIST: Results from the BFR14 randomized phase III trial of the French Sarcoma Group.

Jean-Yves Blay, MD, PhD

12 #10020-Activity of GDC-0941, an inhibitor of phosphoinositol 3 kinase (PI3K), in gastrointestinal stromal tumor (GIST) xenograft and duration of response after discontinuation of treatment in combination with imatinib.

Giuseppe Floris

- Discussion

Margaret von Mehren, MD

13 #10021-Adjuvant treatment of high-risk primary uterine leiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of phase II multicenter trial SARC005.

Martee Leigh Hensley, MD, MSc

14 #10022-Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas.

John Thomas Mullen

15 #10023-A phase II study of neoadjuvant bevacizumab and radiation therapy for resectable soft tissue sarcomas.

Sam S. Yoon

16 #10024-Phase I study of sorafenib plus ifosfamide in patients with advanced soft tissue and bone sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.

Xavier Garcia del Muro

17 #10025-Efficacy and toxicity of sorafenib monotherapy in patients with advanced soft tissue sarcoma failing anthracycline-based chemotherapy.

Alexia Bertuzzi

18 #10026-A stratified phase II trial investigating sorafenib (SORA) in patients (pts) with metastatic or locally advanced angiosarcoma (AS).

Nicolas Penel

- Discussion

Rashmi Chugh, MD

19 #10027-Trabectedin (Tr) as single agent for advanced soft tissue sarcomas (STS) failing standard of care: Interim analysis of 1,400 patients (pts) in an expanded access program study.

Brian Louis Samuels

20 #10028-Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): Results of a pooled analysis of five single-agent phase II studies using the recommended dose.

Ian Robert Judson, MD

21 #10029-Outcomes of patients (pts) with advanced soft-tissue sarcomas (STS) treated in clinical trials (CTs) versus expanded access programs (EAPs): A decade of experience with single-agent trabectedin (Tr).

George D. Demetri

22 #10030-Trabectedin (T) in advanced, pretreated synovial sarcomas (SS): A retrospective analysis of 39 patients (pts) from three European institutions.

Palma Dileo

23 #10031-Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052).

Patrick Schoffski, MD, MPH

24 #10032-Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group study.

Isabelle Ray-Coquard

25 #10033-Time to onset of progression after imatinib interruption and outcome of patients with advanced GIST: Results of the BFR14 prospective French Sarcoma Group randomized phase III trial.

Axel Le Cesne

- Discussion

James E. Butrynski, MD

Session Title: #258: Sarcoma

Session Type: Poster Discussion Session

Date: Tuesday, June 8

Location: S100a

Time: 11:00 AM - 12:00 PM

- Sarcoma

Anette Duensing, MD

- Sarcoma

Mark Agulnik, MD

1 #10009-Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma.

Scott Schuetze

2 #10010-Advanced phase I/II evaluation of tumor-targeted gene delivery: Intravenous retrovector encoding mutant anticyclin G1 as stand-alone therapy for chemotherapy-resistant bone and soft tissue sarcoma.

Kristen N. Ganjoo

3 #10011-Imatinib in the treatment of tenosynovial giant-cell tumor and pigmented villonodular synovitis.

Vinod Ravi

4 #10012-Imatinib mesylate for the treatment of locally advanced and/or metastatic pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).

Philippe Alexandre Cassier

5 #10013-Activity of sorafenib against desmoid tumor/deep fibromatosis (DT/DF).

Mrinal M. Gounder, MD

6 #10014-Sunitinib malate (SM) in alveolar soft part sarcoma (ASPS).

Elena Palassini

- Discussion

Ian Robert Judson, MD

7 #10015-Phase II trial of nilotinib as third-line therapy for gastrointestinal stromal tumor (GIST) patients in Japan.

Toshirou Nishida, MD, PhD, FACS

8 #10016-Nilotinib for patients with advanced GIST who failed imatinib and sunitinib: Negative effect of prior major gastrectomy on exposure to nilotinib.

Kyu-pyo Kim

9 #10017[^]-Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3.

Peter Reichardt

10 #10018-Validation of Joensuu risk criteria for primary resectable gastrointestinal stromal tumors.

Piotr Rutkowski

11 #10019-Correlation of the topography of *KIT* exon 11 mutation with primary GIST location and predictive value for PFS in patients with advanced GIST: Results from the BFR14 randomized phase III trial of the French Sarcoma Group.

Jean-Yves Blay, MD, PhD

12 #10020-Activity of GDC-0941, an inhibitor of phosphoinositol 3 kinase (PI3K), in gastrointestinal stromal tumor (GIST) xenograft and duration of response after discontinuation of treatment in combination with imatinib.

Giuseppe Floris

- Discussion

Margaret von Mehren, MD

13 #10021-Adjuvant treatment of high-risk primary uterine leiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of phase II multicenter trial SARC005.

Martee Leigh Hensley, MD, MSc

14 #10022-Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas.

John Thomas Mullen

15 #10023-A phase II study of neoadjuvant bevacizumab and radiation therapy for resectable soft tissue sarcomas.

Sam S. Yoon

16 #10024-Phase I study of sorafenib plus ifosfamide in patients with advanced soft tissue and bone sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.

Xavier Garcia del Muro

17 #10025-Efficacy and toxicity of sorafenib monotherapy in patients with advanced soft tissue sarcoma failing anthracycline-based chemotherapy.

Alexia Bertuzzi

18 #10026-A stratified phase II trial investigating sorafenib (SORA) in patients (pts) with metastatic or locally advanced angiosarcoma (AS).

Nicolas Penel

- Discussion

Rashmi Chugh, MD

19 #10027-Trabectedin (Tr) as single agent for advanced soft tissue sarcomas (STS) failing standard of care: Interim analysis of 1,400 patients (pts) in an expanded access program study.

Brian Louis Samuels

20 #10028-Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): Results of a pooled analysis of five single-agent phase II studies using the recommended dose.

Ian Robert Judson, MD

21 #10029-Outcomes of patients (pts) with advanced soft-tissue sarcomas (STS) treated in clinical trials (CTs) versus expanded access programs (EAPs): A decade of experience with single-agent trabectedin (Tr).

George D. Demetri

22 #10030-Trabectedin (T) in advanced, pretreated synovial sarcomas (SS): A retrospective analysis of 39 patients (pts) from three European institutions.

Palma Dileo

23 #10031-Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052).

Patrick Schoffski, MD, MPH

24 #10032-Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group study.

Isabelle Ray-Coquard

25 #10033-Time to onset of progression after imatinib interruption and outcome of patients with advanced GIST: Results of the BFR14 prospective French Sarcoma Group randomized phase III trial.

Axel Le Cesne

- Discussion

James E. Butrynski, MD